Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
A Gupta, Y Gonzalez-Rojas, E Juarez… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) disproportionately results in
hospitalization or death in older patients and those with underlying conditions. Sotrovimab is …
hospitalization or death in older patients and those with underlying conditions. Sotrovimab is …
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
SARS-CoV-2 has been spreading around the world for the past year. Recently, several
variants such as B. 1.1. 7 (alpha), B. 1.351 (beta), and P. 1 (gamma), which share a key …
variants such as B. 1.1. 7 (alpha), B. 1.351 (beta), and P. 1 (gamma), which share a key …
Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial
A Gupta, Y Gonzalez-Rojas, E Juarez, MC Casal… - Jama, 2022 - jamanetwork.com
Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
SARS-COV-2 variants: differences and potential of immune evasion
The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing …
(SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing …
The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Since the first described human infection with SARS-CoV-2 in December of 2019 many
subunit protein vaccines have been proposed for use in humans. Subunit vaccines use one …
subunit protein vaccines have been proposed for use in humans. Subunit vaccines use one …
A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations
The infective SARS-CoV-2 is more prone to immune escape. Presently, the significant
variants of SARS-CoV-2 are emerging in due course of time with substantial mutations …
variants of SARS-CoV-2 are emerging in due course of time with substantial mutations …
Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic
novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID …
novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID …
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: a systematic …
Summary BNT162b2 and mRNA‐1273 are two types of mRNA‐based vaccine platforms that
have received emergency use authorization. The emergence of novel severe acute …
have received emergency use authorization. The emergence of novel severe acute …